 |
인쇄하기
취소
|
Hanmi Pharm seeking regulatory approval for new combination formulation of irbesartan and atorvastat
Hanmi Pharmaceutical said Wednesday that it has filed a new drug application for its combination formulation containing irbesartan and atorvastatin to obtain the market authorization from to the Ministry of Food and Drug Safety (MFDS).
On May 15, Hanmi completed its Phase III trials in 22 local university hospitals to evaluate the safety and efficacy of the combination drug in 414 patients.
...
On May 15, Hanmi completed its Phase III trials in 22 local university hospitals to evaluate the safety and efficacy of the combination drug in 414 patients.
...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.